Where do vaccines fit into UAEM policies?
Vaccines are a special case in that they are important for both the developing and developed world, but their lack of profit potential has made pharmaceutical success difficult. The economic reality of this market, coupled with liability concerns and high manufacturing costs (manufacturing fixed costs represents roughly 60% of the expenditure per dose), many pharmaceuticals companies have exited the market. In cases where new vaccines have actually reached the market, prices can be prohibitive. Vaccines would likely be best addressed with policies under our Research Gap proposals.
